| 发明名称 | SiRNA against Cbl-b and optionally IL-2 and IL-12 for use in the treatment of cancer | ||
| 摘要 | The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus permits the therapy of appropriate diseases. | ||
| 申请公布号 | US9186373(B2) | 申请公布日期 | 2015.11.17 |
| 申请号 | US201113977453 | 申请日期 | 2011.12.27 |
| 申请人 | Apeiron Biologics AG | 发明人 | Lametschwandtner Günther;Loibner Hans;Schuster Manfred;Haslinger Isabella;Seidl Sandra |
| 分类号 | C07H21/04;A61K31/713;A61K38/20;C12N15/113;A61K38/21 | 主分类号 | C07H21/04 |
| 代理机构 | Norton Rose Fulbright US LLP | 代理人 | Norton Rose Fulbright US LLP |
| 主权项 | 1. A method of treating cancer in a patient comprising administering at least one Cbl-b inhibitory nucleic acid further defined as an antisense oligonucleotide, siRNA, or shRNA, in combination with at least one NK cell-stimulatory substance further defined as at least one of the following combinations: IL-2 and one or more of IL-12, IL-23, IFN-alpha, or IFN-beta, or any combination thereof; or IFN-alpha and one or both of IL-15 or IL-21; or IL-12 and one or both of IL-15 or IL-7. | ||
| 地址 | Vienna AT | ||